November 25, 2025 a 01:00 pm
CRL: Analysts Ratings - Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. has experienced varying analyst sentiments over the past months. With primary segments focusing on research models, discovery and safety assessment, and manufacturing solutions, it has been a crucial player in the pharmaceutical and biotechnology industries. Recent months show an interesting mix of ratings, signaling a nuanced perspective from analysts. The stock's performance and future potential are influenced by these sectoral strengths and the broader market dynamics.
Historical Stock Grades
Recent analyst ratings for CRL indicate a cautious stance with a predominant "Hold" sentiment. The visual bar representation helps illustrate the distribution of current recommendations from analysts:
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 9 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Throughout the year, there has been a notable shift in analyst ratings, reflecting changing market conditions and company performance:
- An increase in "Hold" ratings suggests analysts' uncertainty regarding immediate growth prospects.
- A consistent presence of "Buy" ratings, albeit declining, indicates continued but cautious optimism.
- Recent months saw slight upticks in "Strong Buy" recommendations, hinting at spotting opportunities by some analysts.
Percentage Trends
The percentage distribution of analyst ratings provides further insight into the evolving sentiment towards CRL:
- Strong Buy decreased significantly from early 2024, indicating more guarded enthusiasm.
- Hold ratings have steadily risen, now constituting the majority, highlighting a neutral stance.
- Overall Buy ratings have declined subtly, consistent with a broader market adjustment period.
- Minimal Sell and Strong Sell ratings reflect relative confidence in the stock's downturn resistance.
Latest Analyst Recommendations
Recent analyst actions primarily involve maintaining existing recommendations, with limited upgrades or downgrades:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-11 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-11-10 | Buy | Buy | TD Cowen |
| 2025-11-06 | Overweight | Overweight | Barclays |
| 2025-11-06 | Outperform | Neutral | Baird |
| 2025-11-06 | Neutral | Neutral | JP Morgan |
Analyst Recommendations with Change of Opinion
Shares of Charles River Laboratories saw pivotal analyst upgrades over recent months, signaling potential positive outlooks:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-06 | Outperform | Neutral | Baird |
| 2025-10-06 | Outperform | Market Perform | William Blair |
| 2025-10-02 | Overweight | Equal Weight | Barclays |
| 2025-09-09 | Buy | Hold | Jefferies |
| 2025-07-09 | Buy | Neutral | Citigroup |
Interpretation
Current analyst sentiment towards Charles River Laboratories suggests a mixed to neutral outlook. The increase in Hold ratings reflects uncertainty about the company's ability to capitalize on market opportunities in the near term. However, sporadic upgrades indicate potential growth if the company effectively leverages its sectoral strengths. Continued upgrades imply potential confidence in long-term strategy despite short-term market volatility. Analysts appear divided, balancing cautious optimism with market realities.
Conclusion
Charles River Laboratories exhibits a delicate balance of risks and opportunities as interpreted by analysts. While caution prevails with numerous Hold ratings, the presence of consistent Buy and occasional Strong Buy recommendations suggests optimism about long-term growth potential. The company's diverse services across critical pharmaceutical and biotechnology segments provide leverage. However, analysts show some restraint, likely assessing broader market challenges. The evolution of recommendations over the next few months remains crucial as the company navigates future opportunities amidst evolving industry dynamics.